logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Trastuzumab deruxtecan for HER2-positive gastric or gastroesophageal junction adenocarcinoma – third-line

< Back

Trastuzumab deruxtecan for HER2-positive gastric or gastroesophageal junction adenocarcinoma – third-line

Drugs

Cancer and Palliative Care

January 2021


Trastuzumab deruxtecan is in development for HER2-positive gastric cancer. HER2 is a type of growth-promoting protein, which can increase cancer cell growth if present (HER2-positive). Gastric cancer originally develops in the stomach, whereas gastro-oesophageal junction cancer originates where the food pipe (oesophagus) joins the stomach. The initial stages of gastric or gastroesophageal cancer are often asymptomatic, with symptoms developing and worsening as the disease progresses.
Trastuzumab deruxtecan consists of an anti-HER2 therapy (trastuzumab) combined with a chemotherapy agent (deruxtecan). Trastuzumab specifically binds to cancer cells that are HER2-positive, which provides a targeted delivery of the deruxtecan inside cancer cells to kill them. This reduces “healthy” cells exposure to the chemotherapy with the potential to reduce negative side effects. If licensed, trastuzumab deruxtecan will offer an additional treatment option for patients whose disease progressed despite previous treatment with other anti-HER2 therapies.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts